International transporter consortium commentary on clinically important transporter polymorphisms

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 1, 2013, Pages 23-26

  Giacomini, K M ^a   Balimane, P V ^b   Cho, S K ^c   Eadon, M ^d   Edeki, T ^e   Hillgren, K M ^f   Huang, S M ^g   Sugiyama, Y ^h   Weitz, D ⁱ   Wen, Y ^d   Xia, C Q ^j   Yee, S W ^a   Zimdahl, H ^k   Niemi, M ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d UNIVERSITY OF CHICAGO   (United States)

^e ASTRAZENECA   (United Kingdom)

^f ELI LILLY AND COMPANY   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

ⁱ SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^j MILLENNIUM PHARMACEUTICALS INC   (United States)

^k BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^l UNIVERSITY OF HELSINKI   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CURCUMIN; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG TRANSPORT; ETHNICITY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MYOPATHY; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ATP-BINDING CASSETTE TRANSPORTERS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; GENE FREQUENCY; HUMANS; MEMBRANE TRANSPORT PROTEINS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84879325410     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.12     Document Type: Review

References (14)

1. Giacomini, K.M. et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010).
2. US Food and Drug Administration. Drug development and drug interactions http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm080499.htm.
3. European Medicines Agency. Guideline on the investigation of drug interactions http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2012/07/WC500129606.pdf (21 June 2012).
4. Tirona, R.G. et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001).
5. Niemi, M., Pasanen, M.K. & Neuvonen P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011).
6. Pasanen, M.K. et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-879 (2006).
7. Link, E. et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
8. van de Steeg, E. et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J. Clin. Invest. 122, 519-528 (2012).
9. Furukawa, T. et al. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm. Res. 26, 469-479 (2009).
10. Keskitalo, J.E. et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86, 197-203 (2009).
11. Chasman, D.I. et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ.Cardiovasc. Genet. 5, 257-264 (2012).
12. Kusuhara, H. et al. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br. J. Pharmacol. 166, 1793-1803 (2012).
13. US Food and Drug Administration. Drug interaction studies. Study design, data analysis, implications for dosing, and labeling recommendations http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf (February 2012).
14. US Food and Drug Administration. Guidance for Industry. Pharmacogenomic data submissions http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ ucm126957.pdf (March 2005).